Skip to main content

Table 2 Linear regression models predicting 48-week change on the ADAS-Cog11 (2A) or CDR-SB (2B) by baseline value of each plasma biomarker after adjusting for age, sex, years of education, APOE ε4, treatment arm, and baseline score

From: Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer’s disease

(2A) Predicting ADAS-Cog change

Plasma biomarker

Std. coefficient

SE

t value

P value

95% CI Lower.bound

95% CI Upper.bound

Bonferroni adjusted P value

GFAP

0.66

0.52

1.28

0.204

−0.36

1.69

1.000

NfL

1.42

0.50

2.82

0.005

0.43

2.41

0.026

P-tau181

0.55

0.51

1.08

0.280

−0.45

1.54

1.000

T-tau

−0.43

0.49

−0.87

0.383

−1.38

0.53

1.000

Aβ42/40

−0.59

0.47

−1.24

0.216

−1.51

0.34

1.000

(2B) Predicting CDR-SB change

Plasma biomarker

Std. coefficient

SE

t value

P value

95% CI Lower.bound

95% CI Upper.bound

Bonferroni adjusted P value

GFAP

0.34

0.16

2.09

0.038

0.02

0.66

0.190

NfL

0.42

0.16

2.61

0.010

0.10

0.73

0.048

P-tau181

0.25

0.16

1.57

0.118

−0.06

0.56

0.589

T-tau

−0.08

0.16

−0.52

0.605

−0.39

0.23

1.000

Aβ42/40

−0.03

0.15

−0.22

0.829

−0.33

0.26

1.000